Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renaming "chemobrain".

Arti Hurria1, George Somlo, Tim Ahles

  • 1City of Hope, Duarte, CA 91010, USA. ahurria@coh.org

Cancer Investigation
|September 21, 2007
PubMed
Summary
This summary is machine-generated.

Cancer survivors often experience cognitive impairment, commonly called "chemobrain." This review suggests "cancer- or cancer-therapy-associated cognitive change" is a more accurate term, encompassing various contributing factors beyond chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer.

medRxiv : the preprint server for health sciences·2025
Same author

Chemotherapy treatment alters DNA methylation patterns in the prefrontal cortex of female rat brain.

Scientific reports·2025
Same author

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.

NPJ breast cancer·2025
Same author

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.

Leukemia·2025
Same author

Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study.

Journal of geriatric oncology·2024
Same author

Comparing sleep measures in cancer survivors: self-reported sleep diary versus objective wearable sleep tracker.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2024
Same journal

Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System.

Cancer investigation·2026
Same journal

Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications.

Cancer investigation·2026
Same journal

Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

Cancer investigation·2026
Same journal

The Heterogeneity of B Cells Potentially Contributes to Metastasis of Clear Cell Renal Cell Carcinomas.

Cancer investigation·2026
Same journal

The Association Between Lymphocyte-Monocyte Ratio, Tumor-Infiltrating Lymphocytes, and Tumor-Associated Macrophages with 3-Year Progression-Free Survival in Advanced Local Stage Nasopharyngeal Cancer Patients.

Cancer investigation·2026
Same journal

<i>In Vivo</i> Pharmacokinetics, Bio-Distribution and anti-Tumor Activity of Docetaxel-Loaded Folate Targeted Biocompatible Polymeric Micelles.

Cancer investigation·2026
See all related articles

Area of Science:

  • Oncology
  • Neuroscience
  • Psychology

Background:

  • Breast cancer survivors report cognitive impairment post-treatment, often termed "chemobrain."
  • Fear of cognitive side effects influences treatment decisions for some patients.
  • Existing literature suggests a multifactorial etiology for cognitive changes in cancer patients.

Purpose of the Study:

  • To review the literature on cognitive impairment in breast cancer survivors.
  • To identify factors contributing to cognitive changes beyond chemotherapy.
  • To propose a more accurate terminology for this phenomenon.

Main Methods:

  • Literature review of studies on cognitive function in cancer survivors.
  • Analysis of factors influencing cognitive impairment.

Related Experiment Videos

  • Synthesis of findings to address definitional and methodological limitations.

    • Main Results:

    • Cognitive impairment in cancer survivors is complex, influenced by chemotherapy, surgery, hormonal therapy, menopause, psychological factors, and comorbidities.
    • Inconsistent definitions and small sample sizes limit current research.
    • Lack of focus on older cancer patients is a significant gap.

    Conclusions:

    • "Chemobrain" is an oversimplification; a broader term like "cancer- or cancer-therapy-associated cognitive change" is more appropriate.
    • Further large-scale, multicenter studies are needed to elucidate mechanisms and impact.
    • Understanding the full spectrum of cognitive changes is crucial for patient care and decision-making.